About Applied Immune Technologies
Applied Immune Technologies is a Healthcare company based in Haifa (Israel) founded in 2006, and was acquired by Adicet Bio in January 2016. TCRL antibodies are developed for therapeutic and diagnostic applications. Applied Immune Technologies has raised $4 million across 2 funding rounds from investors including Adicet Bio and Pontifax Venture Capital. The company was acqui-hired. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting.
Company details
Applied Immune Technologies was founded in 2006 in Haifa, Israel, within the biotechnology sector. Therapeutic molecules are developed for cancer, viral, and autoimmune diseases. T-Cell Receptor-Like (TCRL) antibodies, targeted at intracellular-derived peptides, are created for therapeutic and diagnostic uses. These include pathology diagnostics, vaccine design, validation, monitoring, and antigen presentation analysis in disease states. Technology for discovering TCRL targets is also applied.
- Headquarters Haifa, Israel
- Stage Acquired
- SectorsHealthcare
- Website tcrl.co.il
- Social LinkedIn
- Acquired by Adicet Bio (Jan 2016)
- Total Equity Funding$4M (USD)
in 2 rounds
- Latest Funding Round$600K (USD), Grant
Jan 2011
- InvestorsAdicet Bio
& 1 more
- Acquired byAdicet Bio
(Jan 2016)
Funding Insights of Applied Immune Technologies
Applied Immune Technologies has successfully raised a total of $4M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $600 thousand completed in January 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4M
- Total Rounds 2
- Last Round Grant — $600,000
- First Round $4M
(Apr 2010)
- Investors Count 1
All 2 funding rounds of Applied Immune Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2011 | $600,000 | Grant | – | – | – |
| Apr 2010 | $4M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Applied Immune Technologies
Applied Immune Technologies has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Adicet Bio and Pontifax Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pontifax Venture Capital is focused on life sciences investments. | pontifax.com | Herzeliya, Israel | ||
Immune cell therapies for cancer treatment are developed. | 2014 | adicetbio.com | Menlo Park, United States |
Investor details for Applied Immune Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Applied Immune Technologies
4 dated milestones of Applied Immune Technologies across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Applied Immune Technologies is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Grant, of $600K.
- Exit Acquired by Adicet Bio.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Applied Immune Technologies
Applied Immune Technologies was founded in 2006 and raised its 1st funding round 4 years after it was founded.
Applied Immune Technologies is headquartered in Haifa, Israel. It is registered at Haifa, Haifa District, Israel.
Applied Immune Technologies is a funded company, having raised a total of $4M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Apr 2010.
Applied Immune Technologies was founded in 2006 in Haifa, Israel, within the biotechnology sector. Therapeutic molecules are developed for cancer, viral, and autoimmune diseases. T-Cell Receptor-Like (TCRL) antibodies, targeted at intracellular-derived peptides, are created for therapeutic and diagnostic uses. These include pathology diagnostics, vaccine design, validation, monitoring, and antigen presentation analysis in disease states. Technology for discovering TCRL targets is also applied.
Applied Immune Technologies has 2 investors. Key investors include Adicet Bio, and Pontifax Venture Capital.
Yes. Applied Immune Technologies was acquired by Adicet Bio in January 2016.